Longterm followup of rituximab therapy in patients with rheumatoid arthritis: Results from the Belgian MabThera in Rheumatoid Arthritis registry

Journal of Rheumatology

Volumn 41, Issue 9, 2014, Pages 1761-1765

  De Keyser, Filip ^a   Hoffman, Ilse ^b   Durez, Patrick ^d   Kaiser, Marie Joëlle ^c   Westhovens, Rene ^e   De Meulenaere, ^f   Leon, ^f   De Keyser, ^a,g   Van Den Bosch, ^a,g   Maertens, ^h   Vandevyvere, ⁱ   Raeman, ^j   Ghyselen, ^g   Castro, ^k   Stappaerts, ^k   Reychler, ^l   Lensen, ^m   De Brabanter, ⁿ   Maeyaert, ⁿ   Ackerman, ^o   Luyten, ^o   De Clercq, ^b   Hoffman, ^b   Schatteman, ^b   D'Hondt, ^p   Peene, ^p   Maenaut, ^g   Daumerie, ^g   Docquier, ^g   Halleux, ^g   Fontaine, ^q   Cremer, ^g   Mathy, ^g   Martin, ^g   Daens, ^r   Fernandez Lopez, ^r   Jeukens, ^c   Nizet, ^c   Kaiser, ^c   Lust, ^c   Ribbens, ^c   Di Romana, ^s   Schreiber, ^t   Dall'Armelina, ^u   Jardinet, ^u   Steinfeld, ^v   Brigode, ^w   Tant, ^g   Francois, ^x   Van Bruwaene, ^y   Van Den Bergh, ^z   Zangerle, ^g   Declerck, ^aa   Mindlin, ^ab   Durez, ^ac   Ravelingien, ^ad   Van Essche, ^g   Cheroutre, ^g   Van Den Bossche, ^g   Volders, ^ae   Herman, ^g   Coutellier, ^af   Vanneuville, ^ag   Gyselbrecht, ^ah   Van Den Berghe, ^ah   Verbruggen, ^a,ai   Aspeslagh, ^a   Carron, ^a   Elewaut, ^a   Malfait, ^a   Mielants, ^a   Piette, ^a   Stubbe, ^a   Vander Cruyssen, ^a   Westhovens, ^aj   Lechkar, ^ak   Corluy, ^al   Hirsch, ^am   Berghs, ^an   Geussens, ^an   Vanhoof, ^an   more..

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b SINT AUGUSTINUS HOSPITAL   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^f Ambroise Pare hospital   (Belgium)

^g AZ Alma ^*  (Belgium)

^h Algemeen Ziekenhuis Damiaan Oostende   (Belgium)

ⁱ AZ Groeningen   (Belgium)

^j AZ Jan Palfijn Gallifort   (Belgium)

^k AZ Maria Middelares   (Belgium)

^l AZ Oudenaarde   (Belgium)

^m AZ Seruys   (Belgium)

ⁿ AZ St Lucas   (Belgium)

^o AZ Sint Lucas   (Belgium)

^p General Hospital St Jan   (Belgium)

^q UNIVERSITY OF LIÈGE   (Belgium)

^r BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^s SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^t Centre Hospitalier Universitaire de Tivoli   (Belgium)

^u Clinique Notre Dame de Grace   (Belgium)

^v Saint Jean Clinic of Brussels   (Belgium)

^w Clinique Saint Pierre of Ottignies   (Belgium)

^x Europaziekenhuizen St Michiel   (Belgium)

^y Heilig Hart Ziekenhuis   (Belgium)

^z Service de Dermatologie   (Belgium)

^aa IMELDA HOSPITAL   (Belgium)

^ab IRIS   (Belgium)

^ac UCL Mont Godine   (Belgium)

^ad OLV HOSPITAL   (Belgium)

^ae Reumacentrum   (Belgium)

^af St Luc Bouge   (Belgium)

^ag SZ Roeselare   (Belgium)

^ah SZA   (Belgium)

^ai UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^aj UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^ak ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^al VIRGA JESSE HOSPITAL   (Belgium)

^am Zitha Kliniek   (Luxembourg)

^an DEPARTMENT OF CARDIOLOGY   (Belgium)

more..

Author keywords

Antirheumatic agents; Cohort study; DAS28; Rheumatoid arthritis; Rituximab

Indexed keywords

ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ARTHRITIS, RHEUMATOID; FEMALE; HUMAN; MALE; MIDDLE AGED; REGISTER; RETREATMENT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RETREATMENT; TREATMENT OUTCOME;

EID: 84906874847     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131279     Document Type: Article

References (16)

1. Bokarewa M, Lindholm C, Zendjanchi K, Nadali M, Tarkowski A. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol 2007;66:476-83. (Pubitemid 47394564)
2. Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial. J Rheumatol 2011;38:2548-56.
3. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
4. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-21.
5. Lee YH, Bae S-C, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2011;31:1493-9.
6. Keystone EC, Cohen SB, Emery P, Kremer JM, Dougados M, Loveless JE, et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 2012;39:2238-46.
7. Dudler J, Finckh A, Kyburz D, Langenegger T, Möller B, Schmiedel U, et al. Swiss consensus statement: Recommendations for optimising re-treatment with MabThera (rituximab) in rheumatoid arthritis. Swiss Med Wkly 2010;140:w13073.
8. Vander Cruyssen B, Durez P, Westhovens R, Kaiser M-J, Hoffman I, De Keyser F. The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies. Arthritis Res Ther 2010;12:R169.
9. Slimani S, Lukas C, Combe B, Morel J. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine 2011;78:484-7.
10. Du Pan SM, Scherer A, Gabay C, Finckh A. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 2012;71:997-9.
11. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011;70:1575-80.
12. Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res 2012;64:1108-15.
13. Finckh A, Ciurea A, Brulhart L, Möller B, Walker UA, Courvoisier D, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010;69:387-93.
14. Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
15. Kekow J, Mueller-Ladner U, Schulze-Koops H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure. Biologics 2012;6:191-9.
16. Solau-Gervais E, Prudhomme C, Philippe P, Duhamel A, Dupont- Créteur C, Legrand JL, et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine 2012;79:281-4.